Jade Biosciences Inc Ordinary Shares JBIO 深 滬
已收盤 12-24 16:00:00 美东时间
16.53
+0.180
+1.10%
華盛通- 最 高17.27
- 今 開16.48
- 成交量 13.04万股
- 最 低 16.4325
- 昨 收 16.35
- 總市值 7.60亿
- 52周最高 17.71
- 市盈率 靜 --
- 換手率 0.28%
- 52周最低 -5.60
- 委 比 -74.75%
- 總股本 4599.49万
- 歷史最高 1050.525
- 量 比 0.18
- 振 幅 5.12%
- 歷史最低 -40.25
- 每 手 1
- 風險率 3.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Jade Biosciences Files For Offering Of 3.2M Shares Of Common Stock By Selling Stockholder
3,214,286 SharesCommon StockOffered by the Selling Stockholder This prospectus relates to the proposed resale or other disposition by the selling stockholder identified herein (the "Selling Stockholder") of up
12-23 05:41
Jade Biosciences Raises $45M in Private Stock Offering Of 3.21M Shares At $14/Share To Advance Autoimmune Drug Research
Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has entered into a
12-15 20:08
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Praxis Precision Medicine (NASDAQ:PRAX) shares moved upwards by 33.6% ...
12-06 01:05
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
11-26 10:07
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
11-19 11:01
Guggenheim Maintains Buy on Jade Biosciences, Raises Price Target to $17
Guggenheim analyst Vamil Divan maintains Jade Biosciences (NASDAQ:JBIO) with a Buy and raises the price target from $14 to $17.
11-18 22:12
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Dow Jones index falling more than 100 points o...
11-18 00:39
Jade Biosciences Q3 EPS $(0.48) Beats $(0.66) Estimate
Jade Biosciences (NASDAQ:JBIO) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.66) by 27.27 percent.
11-14 05:33
Jade Biosciences To Present New Preclinical Safety, Translational Data For Immunoglobulin A Nephropathy Candidate JADE101 American Society of Nephrology Kidney Week
SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("the Company" or "Jade"), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing
10-18 04:09
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025
Jade Biosciences will present new preclinical safety and translational data for JADE101, its lead investigational candidate for immunoglobulin A nephropathy (IgAN), during two poster sessions at the American Society of Nephrology (ASN) Kidney Week 2025. JADE101 is a potentially best-in-class disease-modifying anti-APRIL monoclonal antibody designed to selectively inhibit APRIL in patients with IgAN. The therapy is currently being evaluated in a P...
10-17 20:05
